- Home
- CHI vs SLS Comparison
CHI vs SLS Comparison
Compare CHI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | SLS |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 924.5M |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CHI | SLS |
|---|---|---|
| Price | $12.72 | $9.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 165.1K | ★ 8.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.00 | $1.39 |
| 52 Week High | $12.75 | $9.24 |
Technical Indicators
Market Signals| Indicator | CHI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 72.54 |
| Support Level | $10.84 | $3.72 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.25 | 0.87 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 97.28 | 96.64 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.